Inflammatory Disease Interest Group

Click here to see our meeting schedule.

The Inflammation interest group brings together scientists at all experience levels with an interest in chronic inflammatory disease research. Inflammation is a complex biological response that occurs in all tissues of the body, typically in response to harmful stimuli, such as pathogens, irritants, or following repeated mechanical injury, with genetics playing an additional role. Although inflammation can be a protective response, if the causative agent is persistent or the mechanisms that regulate the initiation, maintenance, or resolution of the inflammatory response become dysregulated, it can evolve into a pathophysiological response, as is seen in chronic autoimmune, neurodegenerative, fibrotic, and allergic diseases. Inflammation is also a central driver of tumor progression. The purpose of this SIG is to encourage better communication, thoughtful discussions, and NIH-wide collaboration so that new treatment modalities might be developed for the many chronic inflammatory and fibrotic diseases that impact human health. The group convenes daylong symposia two or three times per year on various topics focused around the general theme of “chronic inflammatory disease” and host a bi-monthly seminar series focused on basic and translational aspects of inflammation.

The steering committee is:
Grégoire Altan-Bonnet (NCI)
Jason Brenchley (NIAID)
Michael Fessler (NIEHS)
Mariana Kaplan (NIAMS)
Nehal Mehta (NHLBI)
Daniel Reich (NINDS)

The group is open to all persons within NIH and associated agencies (FDA, USDA, etc) who share an interest in basic and translational inflammation research. To join the listserv, link to https://list.nih.gov/cgi-bin/wa.exe?A0=inflam-dis-l.

Mailing List

To join the Inflammatory Disease Interest Group mailing list, please visit the Inflammatory Disease Interest Group Listserv home page, then click the “Subscribe or Unsubscribe” link in the right sidebar.

Chair

Scientific Focus Areas

This page was last updated on Thursday, August 12, 2021